Table 2. Relationship of MCC recurrence risk to selected clinical characteristics.
Hazard ratios are shown for MCC recurrence risk. On multivariate Cox regression, MCPyV oncoprotein antibody seropositivity at diagnosis was associated with significantly improved recurrence-free survival. Stage and sex were also significant. N=219 patients with newly diagnosed MCC.
| Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|
|
|
||||||
| Hazard Ratio | 95% CI | P-Value (global) | Hazard Ratio | 95% CI | P-value (global) | |
| Stage | < 0.01 | <0.01 | ||||
|
| ||||||
| I | 1.00 | Reference | 1.00 | Reference | ||
| II | 2.49 | 1.18-5.25 | 3.13 | 1.42-6.90 | ||
| III | 2.48 | 1.43-4.30 | 3.00 | 1.68-5.33 | ||
| IV | 6.89 | 2.87-16.52 | 8.46 | 3.34-21.43 | ||
|
| ||||||
| Sex | <0.01 | 0.02 | ||||
|
| ||||||
| Female | 1.00 | Reference | 1.00 | Reference | ||
| Male | 2.11 | 1.29-3.47 | 1.79 | 1.08-2.95 | ||
|
| ||||||
| Age | 0.18 | 0.19 | ||||
|
| ||||||
| ≤65 years | 1.00 | Reference | 1.00 | Reference | ||
| >65 years | 1.38 | 0.86-2.20 | 1.40 | 0.85-2.32 | ||
|
| ||||||
| Immune suppression | 0.18 | 0.21 | ||||
|
| ||||||
| No | 1.00 | Reference | 1.00 | Reference | ||
| Yes | 1.54 | 0.81-2.93 | 1.56 | 0.78-3.12 | ||
|
| ||||||
| Oncoprotein antibody | 0.1 | 0.04 | ||||
|
| ||||||
| Seronegative | 1.00 | Reference | 1.00 | Reference | ||
| Seropositive | 0.68 | 0.44-1.08 | 0.58 | 0.36-0.97 | ||